European and FDA approval of Sephience (sepiapterin) with broad labeling for PKU - - Global launch underway in Europe and U.S. - - Total Q2 Revenue of $179M - ...

LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.